Zaltrap Disease Interactions
There are 6 disease interactions with Zaltrap (ziv-aflibercept).
Ziv-aflibercept (applies to Zaltrap) GI perforation
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Perforation, Inflammatory Bowel Disease
Gastrointestinal (GI) perforation including fatal GI perforation can occur in patients receiving ziv-aflibercept. Care should be exercised when using this agent in patients at risk of GI perforation. It is recommended to monitor patients for signs and symptoms of GI perforation and discontinue therapy in patients who experience GI perforation.
Ziv-aflibercept (applies to Zaltrap) hemorrhage
Major Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding
Ziv-aflibercept can impair wound healing, cause gastrointestinal (GI) perforation, and cause severe and sometimes fatal hemorrhages including GI hemorrhage. It is recommended to suspend the use of ziv-aflibercept for at least 4 weeks prior to elective surgery and do not resume treatment for at least 4 weeks following major surgery and until the surgical wound is fully healed. It is recommended to discontinue the use of this agent in patients with compromised wound healing.
Ziv-aflibercept (applies to Zaltrap) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
No dosage modification is recommended for patients with mild and moderate hepatic impairment. Monitor closely when administering ziv-aflibercept to patients with severe hepatic impairment as this agent has not been studied in these patients.
Ziv-aflibercept (applies to Zaltrap) hypertension
Moderate Potential Hazard, Moderate plausibility.
The use of ziv-aflibercept increases the risk of Grade 3-4 hypertension. It is recommended to monitor blood pressure every two weeks or more frequently as clinically indicated during treatment. Patients should be treated with appropriate antihypertensive therapy and continue monitoring blood pressure regularly. Care should be exercised when treating patients with preexisting hypertension. Temporarily suspend treatment in patients with uncontrolled hypertension until controlled and permanently reduce the dose to 2 mg per kg for subsequent cycles. Discontinue therapy with ziv-aflibercept in patients with hypertensive crisis or hypertensive encephalopathy.
Ziv-aflibercept (applies to Zaltrap) neutropenic complications
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia
The use of ziv-aflibercept may increase the incidence of neutropenic complications (febrile neutropenia and neutropenic infection). It is recommended to monitor CBC with differential count at baseline and prior to initiation of each cycle of therapy. Exercise care when using this agent in patient with neutropenic complications. Delay the use of ziv-aflibercept until neutrophil count is at or above 1.5 × 109/L.
Ziv-aflibercept (applies to Zaltrap) proteinuria
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Nephrotic Syndrome, Thrombotic Thrombocytopenic Purpura, Renal Dysfunction, Thrombocytopenia, Hemolytic Uremic Syndrome
Severe proteinuria, nephrotic syndrome, and thrombotic microangiopathy (TMA) occurred more frequently in patients treated with ziv-aflibercept. It is recommended to monitor proteinuria by urine dipstick analysis and/or urinary protein creatinine ratio for the development or worsening of proteinuria during therapy. Suspend or discontinue treatment in patients who develop nephrotic syndrome or TMA as appropriate.
Switch to professional interaction data
Zaltrap drug interactions
There are 180 drug interactions with Zaltrap (ziv-aflibercept).
Zaltrap alcohol/food interactions
There is 1 alcohol/food interaction with Zaltrap (ziv-aflibercept).
More about Zaltrap (ziv-aflibercept)
- Zaltrap consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.